| scholarly article | Q13442814 |
| P2093 | author name string | Igor Frank | |
| Matthew K Tollefson | |||
| Stephen A Boorjian | |||
| R Houston Thompson | |||
| William R Sukov | |||
| R Jeffrey Karnes | |||
| John C Cheville | |||
| Prabin Thapa | |||
| Brian A Costello | |||
| Robert F Tarrell | |||
| Steven A Schneider | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. | Q33751191 | ||
| HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial | Q34194672 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| Imaging of HER-2 overexpression in tumors for guiding therapy | Q34657594 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients | Q36836840 | ||
| Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma | Q36910400 | ||
| Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder | Q37836129 | ||
| Invasive micropapillary urothelial carcinoma of the bladder | Q39884245 | ||
| Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases | Q44271939 | ||
| Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 24 cases. | Q51530779 | ||
| Dynamic and modern: bringing the ethics of phase I trials up to date. | Q53218862 | ||
| HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. | Q54594744 | ||
| Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma | Q72850970 | ||
| HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial | Q79816337 | ||
| Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases | Q81364627 | ||
| Prognostic significance of measured depth of invasion of urothelial carcinoma of the bladder compared to the 2010 American Joint Committee on Cancer pT2 and pT3 classifications | Q85013810 | ||
| Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis | Q85377312 | ||
| P433 | issue | 5 | |
| P921 | main subject | Erb-b2 receptor tyrosine kinase 2 | Q415271 |
| Radical cystectomy | Q111329312 | ||
| P304 | page(s) | 758-764 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. | |
| P478 | volume | 27 |
| Q90024930 | Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q |
| Q31138373 | Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review? |
| Q47998264 | Characteristics and clinical significance of histological variants of bladder cancer. |
| Q35905097 | Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder. |
| Q36666214 | Consensus and conflict in invasive micropapillary carcinoma: a case report and review of the literature |
| Q36724623 | HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder |
| Q33676976 | High-Grade Urothelial Carcinoma of Bladder Transforming to Micropapillary Variant on Follow-Up |
| Q34028470 | Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib |
| Q93182670 | Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation |
| Q52618828 | Intratumoral Heterogeneity of ERBB2 Amplification and HER2 Expression in Micropapillary Urothelial Carcinoma. |
| Q53070572 | Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. |
| Q33910532 | Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment |
| Q61450653 | Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder |
| Q35407910 | Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis |
| Q54269156 | Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. |
| Q27009469 | Targeted therapy in advanced bladder cancer: what have we learned? |
| Q26827175 | The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo |
| Q38269990 | Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer |
| Q93190827 | Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants |
| Q89665021 | Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas |
Search more.